TERAIMMUNE, INC.
GERMANTOWN, MD · Founded 2019 · CIK 0001958944 · Biotech · Private
Personalized fVIII-specific TCR-engineered regulatory T cell (Treg) therapy for hemophilia A patients with inhibitor antibodies
teraimmune.us →- Grants
- $450K
- 2 awards
- Sector median: 1
- Raised
- $3.0M
- 1 Form D · Dec 2022
- 45 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 1 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Factor VIII (fVIII)-specific therapeutic Tregs and related cGMP manufacturing process for hemophilia A patients with inhibitors | $224,941 | |
| Federal grant | Department of Health and Human Services · Phase I · Factor VIII (fVIII)-specific therapeutic Tregs and related cGMP manufacturing process for hemophilia A patients with inhibitors | $224,941 | |
| Private capital raised | Form D · SEC | $2,962,500 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2332 | Secura Bio, Inc. | — | $50M |
| 2333 | NEMAGEN DISCOVERIES INC | — | — |
| 2334 | NEMAMETRIX, INC | — | $9.4M |
| 2335 | TERAIMMUNE, INC. | — | $3.0M |
| 2336 | Decibel Therapeutics | — | $63M |
| 2337 | 3P BIOTECHNOLOGIES, INC. | — | — |
| 2338 | Mythic Therapeutics | — | $53M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Yong Chan Kim, PhDDirector · Executive Officer
- Jihoon ParkDirector · Executive Officer
Patents
- Combined Administration Composition For Preventing Or Treating Atopic Dermatitis, Comprising Function-enhanced Stem Cells And Regulatory T Cellsapplication
- Method Of Producing Regulatory T Cells By Culturing Regulatory T Cells Obtained From Umbilical Cord Bloodapplication
- Method Of Producing Regulatory T Cells By Culturing Regulatory T Cells Obtained From Umbilical Cord Bloodgranted
- Method Of Producing Regulatory T Cells By Culturing Regulatory T Cells Obtained From Umbilical Cord Bloodapplication
- Method Of Producing Regulatory T Cells By Culturing Regulatory T Cells Obtained From Umbilical Cord Bloodapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.